Sensorion Announces an Oral Presentation of New SENS-401 Preclinical Data at ISIET 2019 in Hannover
07 Novembre 2019 - 7:30AM
Business Wire
An oral presentation on the capacity of
SENS-401 to reduce central auditory neuron loss after acoustic
trauma in preclinical studies
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a
pioneering clinical-stage biopharmaceutical company which
specializes in the development of novel therapies to restore, treat
and prevent inner ear diseases such as hearing loss, tinnitus and
vertigo, has contributed an oral presentation at the 2nd
International Symposium on Inner Ear Therapeutics (ISIET 2019) held
in Hannover (Germany), from the 4th to the 6th of November,
2019.
In the session “Outcome measures and clinical trials”, the talk
entitled “Oral SENS-401 Reduces Central Auditory Neuronal Loss
after Acoustic Trauma in NMRI Mice” presented studies performed in
collaboration with researchers at the Unfallkrankenhaus Berlin
& Charité Medical School (Berlin, Germany) that investigated
the potential of orally administered SENS-401 to protect against
loss of central auditory neurons after acoustic trauma induced
hearing loss in NMRI mice.
Most research and models of sensorineural hearing loss focus on
peripheral damage and potential therapeutic targets in the
peripheral auditory structures of the cochlea. However, damage to
central auditory structures can contribute significantly to e.g.
tinnitus, reduced speech intelligibility and other central auditory
processing deficits.
To determine the potential for protection against central
auditory cell death in an established model, SENS-401 or placebo
was administered orally to NMRI mice for 14 days after exposure to
acoustic trauma. Subsequently, the number of surviving neurons in
the central auditory structures of the ventral cochlear nucleus
(VCN) and inferior colliculus (IC) were determined using
histological methods. SENS-401 treatment significantly increased
the number of surviving neurons in the VCN and IC compared to
placebo treatment.
These results suggest that SENS-401, in addition to the
ability to preserve sensory cells and hearing function peripherally
in the cochlea, could also reduce the loss of central auditory
neurons in sensorineural hearing loss pathologies. This could
confer additional clinical treatment benefits such as reduced
incidence/severity of tinnitus or central auditory processing
deficits for patients.
About SENS-401
SENS-401, arazasetron besylate, is a drug candidate that aims to
protect and preserve inner ear tissue from damage that can cause
progressive or sequelar hearing impairment. A small molecule that
can be taken orally or via an injection, SENS-401 has received
Orphan Drug Designation in Europe for the treatment of sudden
sensorineural hearing loss, and Orphan Drug Designation from the US
FDA for the prevention of platinum-induced ototoxicity in pediatric
population. It has received Investigational New Drug (IND)
clearance from the US Food and Drug Administration (FDA).
About Sensorion
Sensorion is a pioneering clinical-stage biopharmaceutical
company, which specializes in the development of novel therapies to
restore, treat and prevent inner ear diseases such as hearing loss,
vertigo and tinnitus. Its clinical-stage portfolio includes two
phase 2 products: Seliforant (SENS-111) under investigation for
acute unilateral vestibulopathy and Arazasetron (SENS-401) for
sudden sensorineural hearing loss (SSNHL). Sensorion has built a
unique R&D technology platform to expand its understanding of
the physiopathology and etiology of inner ear related diseases
enabling it to select the best targets and modalities for drug
candidates. The Company has also identified biomarkers to improve
diagnosis and treatment of these underserved illnesses. Sensorion
is launching in the second half of 2019 two preclinical gene
programs aiming at correcting hereditary monogenic forms of
deafness including Usher Type 1 and deafness caused by a mutation
of the gene encoding for Otoferlin. The Company is uniquely placed
through its platforms and pipeline of potential therapeutics to
make a lasting positive impact on hundreds of thousands of people
with inner ear related disorders; a significant global unmet need
in medicine today. www.sensorion-pharma.com
Label: SENSORION ISIN: FR0012596468 Mnemonic:
ALSEN
Disclaimer
This press release contains certain forward-looking statements
concerning Sensorion and its business. Such forward looking
statements are based on assumptions that Sensorion considers to be
reasonable. However, there can be no assurance that such
forward-looking statements will be verified, which statements are
subject to numerous risks, including the risks set forth in the
"Document de reference" registration document filed with the
"Autorité des Marchés Financiers" (AMF French Financial Market
Authority) on September 7th, 2017 under n°R.17-062 and to the
development of economic conditions, financial markets and the
markets in which Sensorion operates. The forward-looking statements
contained in this press release are also subject to risks not yet
known to Sensorion or not currently considered material by
Sensorion. The occurrence of all or part of such risks could cause
actual results, financial conditions, performance or achievements
of Sensorion to be materially different from such forward-looking
statements. This press release and the information that it contains
do not constitute an offer to sell or subscribe for, or a
solicitation of an offer to purchase or subscribe for, Sensorion
shares in any country. The communication of this press release in
certain countries may constitute a violation of local laws and
regulations. Any recipient of this press release must inform
oneself of any such local restrictions and comply therewith.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191106005839/en/
Sensorion Nawal Ouzren CEO contact@sensorion-pharma.com
Tel: +33 467 207 730 Catherine Leveau Finance & Financial
communication catherine.leveau@sensorion-pharma.com Tel: +33 467
207 730
Grafico Azioni Sensorion (EU:ALSEN)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Sensorion (EU:ALSEN)
Storico
Da Apr 2023 a Apr 2024